Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of UKDiss.com.
Flow Cytometric Analysis of TGF-β -induced Downregulation of Different Phosphatases Dependent E-cadherin cell-cell adhesion of HepG2 Cell Lines
There are various types of Hepatocellular carcinoma (HCC) cell lines. Among these, HepG2 has been used most frequently in many research experiments because the cells carries a huge amount of cellular functions like general hepatocytes such as hepatocyte-specific cell surface receptors expression and plasma proteins synthesis-secretion. Furthermore, HepG2 cell line exhibits characterized morphological and functional differentiation in vitro. That is why this cell line is a perfect model to investigate intracellular trafficking (Xia et al. 2013).
Epithelial cells lose their cell-cell adhesion and cell polarity through the epithelial–mesenchymal transition (EMT). Epithelial structure is supported by cell-cell interactions involving compact junctions, cadherin based adherens junctions connected to the actin cytoskeleton. Epithelial cells demonstrate mentionable amounts of E-cadherin, a calcium-dependent cell-cell adhesion molecule (Radisky 2005). E-cadherin responds to TGFβ regulated pathways and thus the cells expresses TGFβ-dependent growth inhibition (Miettinen et al. 1994).
Transforming growth factor beta (TGF-β) is a multifunctional cytokine of transforming growth factor superfamily (Massague 2012). TGF-β is associated with liver fibrogenesis which is followed by a decreased liver function, which often refers clinically as liver cirrhosis. TGFβ has growth-suppressive nature on epithelial cells. In most epithelial tumour cells, TGFβ treatment ends in epithelial dedifferentiation with cell aggregation reduction and cellular migration enhancement. TGFβ induce biochemical, morphological and transcriptional changes towards EMT. Using serine/threonine kinase receptors and SMAD proteins, TGF-β signals from the membrane to the nucleus (Massaous and Hata 1997). The activated TGF-β receptor induces phosphorylation of these SMAD proteins (Eppert et al. 1996; Lagna et al. 1996; Macias-Silva et al. 1996; Nakao et al. 1997; Zhang et al. 1996) that translocate towards the nucleus (Zhang, Musci and Derynck 1997), followed by the regulation of transcriptional responses (Chen, Rubock and Whitman 1996; Kim et al. 1997).
The sum of protein kinase and protein phosphatase activity is reflected in terms of level in protein phosphorylation, in vivo. Phosphatases draw major regulators of E-cadherin-mediated cell-cell adhesion. There is a direct involvement of distinct Protein Tyrosine Phosphatases (PTPs) with the E-cadherin proteins. PTPs-inhibition results in cellular adhesion destabilisation and migration enhancement. Phosphatidylinositol 3-kinase (PI3-kinase) and the phosphatase PTEN are involved with the E-cadherin adhesion complex, play a vital role in TGFβ -induced phosphorylation, which results in a decreased cell-cell adhesion with increased cell migration (Bhowmick et al. 2001; Vogelmann et al. 2005). TGFβ also plays a double role in tumorigenesis (Caja et al. 2011). If the cells avoid pro-apoptotic action may undergo EMT (Fabregat et al. 2014), further obtain increased migratory (Bertran et al. 2013) and drug resistance capabilities (Fernando et al. 2015).
On the other hand, in vitro and in vivo models, the TGF-β kinase inhibitor LY2109761 up-regulates E-cadherin expression in HCC cell migration/invasion and EMT (Fransvea et al. 2008). It blocks (Figure 1) the TGF-β signaling in HCC cells (Giannelli et al. 2002; Jonas et al. 2001; Sumie et al. 2008). In fact, LY2109761 demonstrate a stronger anti-angiogenic effect which resulting in tumoral growth inhibition (Mazzocca et al. 2009).
Figure 1: The activity of TGF-β and TGF-β kinase inhibitor LY2109761 upon HepG2 Cell Lines. The figure is partially adapted (Serrano-Gomez, Maziveyi and Alahari 2016).
In this report, the impact of TGF-β (30ng/ml for 48hrs) and TGF-β kinase inhibitor LY2109761 (1M for 48hrs) treated Hep G2 cell lines have been investigated through flow cytometry after a successful staining of the adhesion junction protein E-cadherin with Green Fluorescent Protein (GFP) conjugated monoclonal antibody.
Human hepatoma cells were trypsinised to hydrolyse (breakdown) extracellular and cell surface proteins involved in cell-cell and cell-flask attachment thus releasing cells into suspension. The cells were then counted by using haemocytometer for antibody staining. The cells were then fixed and stained with a GFP conjugated monoclonal antibody for a flow cytometer experiment (Cell Culture and Antibody Technology Labs Handout 1718OCTJAN).
After 3 days incubation, human HepG2 cells were treated with TGF- β (30ng/ml) and TGF-β receptor kinase inhibitor (LY2109761) (1M) for 48 hours. Then the cells were trypsinised with trypsin/EDTA solution and stained with Methylene Blue. Haemocytometer was used to count the cell viability.
Figure 2: The percentage viability of different cell line treatment
Approximately 61 cells were found live for LY2109761 treated cell suspension whereas only 8 cells were identified as dead cells. The cells which were treated with only TGF-β, about 12 cells were live and 4 cells were dead. No live cells were identified for no treatment suspension, however 5 dead cells were found under the microscope. Using proper calculation, it was demonstrated that the percentage viability for LY2109761 treated sample was 88.41% whereas the TGF-β treated sample showed 75% viability rate. As there was no viable cells for no treatment sample, the viabilty percentage was zero (Figure 2).
About 1220000, 240000 and 0 cells were identified as viable per cm3 for LY2109761, TGF-β, no treatment sample respectively (Figure 3). Approximately 100000 viable cells from each treatment were directly stained with with a GFP conjugated monoclonal antibody for a flow cytometer (FACS) experiment.
Figure 3: The total number of viable cells per cm3 for different cell line treatment
Figure 4: Different fluorescence level for each of the individual group treatment by FACS
Total six individual experiments were performed to analyse the data more critically. The FACS exhibited different fluorescence level for each of the individual group treatment (Figure 4). The FACS also produced some dot plots (Figure 5) and histograms according to the fluorescence level (Figure 6).
Figure 5: Flow Cytometric Dot Plot of different cell line treatment measuring forward scatter and side scatter
Figure 6: Flow Cytometric fluorescence histogram of different cell line treatment measuring GFP conjugated monoclonal antibody. (A) indicates the no treatment sample whereas (B) and (C) represent the TGF-β and TGF-β receptor kinase inhibitor (LY2109761) treatment respectively.
TGF-β is a major growth inhibitor and apoptosis inducer in hepatocytes (Siegel and Massague 2003). However, although it plays role as a tumour suppressor (Bierie and Moses 2006; Levy and Hill 2006), it can also come up with tumour progression and metastasis through EMT (Bierie and Moses 2006), which results in enhanced cell migration and invasion (Gotzmann et al. 2002; Pagan et al. 1999).
In this experiment, TGF-β is identified as a key factor in the microenvironment that takes part in the induction of EMT process. E-cadherin which is dependent on calcium (Ca2+)ions to perform, ensures cells adhesions within tissues or in monolayer. By chelating Ca2+, E-cadherins become inactivated which results in the dissociation of cells or tissues (van Roy and Berx 2008). Trypsin/EDTA was employed to breakdown the attachment between cell-cell and cell-flask attachment (Fong, Duceppe and Hoemann 2017). Then methylene bluewas used to stain the cell for counting on haemocytometer. Methylene Blue, a metachromatic stain was used which makes the DNA in the nucleus to stand out for observation to see the cell clearly under the light microscope. Methylene Blue can be transformed to a colourless substance, while the dead cells retain the blue colour of the stain by metabolically active viable cells with dehydrogenase activity (Kucsera, Yarita and Takeo 2000). In haemocytometer, relatively more cells were found live for LY2109761 treated cell suspension than any other treatment. It was due to poor maintenance of the cells. The cells were shaken for more than enough times and was process for a long time which results in unexpected dead cells (Lorsch, Collins and Lippincott-Schwartz 2014). The sufficient live cells were then fixed using paraformaldehyde to increase the cells permeability which allowed stained antibodies to access intracellular structures (Yuan et al. 2017). In case of antibody selection, monoclonal antibodies were used because polyclonal antibodies tend to bind multiple aspects of the same antigen, causing problem in data analysis when used in flow cytometry. Conversely, homogeneous monoclonal antibodies acts differently and effectively label cells (Pelletier et al. 2017). For the stain, Green Fluorescent Protein (GFP), a 488nm fluorescent cytochrome was used which is identifiable in the green light wavelength (Adan et al. 2017; Svendsen et al. 2017). Binding with monoclonal antibodies, it directly stains the adhesion junction protein E-cadherin (Sanchez et al. 2014), therefore, the cells.
The GFP-conjugated cells produce characterized histograms for the flow cytometry. A flow cytometer can identify the presence of a fluorophore and also quantify the relative measurement of a fluorophore within a cell (Evans et al. 2017). Dead cells show higher side scatter and lower forward scatter than the viable cells as well as in histograms, live cells exhibit higher peak than dead cells (Adan et al. 2017). From the results, it can be seen that LY2109761 treated cells have the highest peak in the histograms and thus result in maximum fluorescence level. It was due to more stained E-cadherin. As it is well known that TGFβ induce morphological changes to EMT by protein phosphorylation; individual phosphatases plays an important role in E-cadherin-mediated cell-cell adhesion. In this study, it is assumed that TGFβ inhibits the activity of phosphatases which results in the induction of EMT process. TGFβ treatment enhanced phosphorylation, which resulted in dissociation of the E-cadherin from the actin cytoskeleton and reduced cell-cell adhesion (Adan et al. 2017; Bhowmick et al. 2001). By contrast, LY2109761 inhibited the process of phosphorylation that is why there was no EMT process to take place so produce high peak in the histograms. Moreover, relatively higher side scatter and lower forward scatter in dot plots also indicated more viability for LY2109761 treated cells.
There were also some dots and fluorescence for the no treatment sample. It was happened due to failure of maintaining good aseptic technique that is why there might be some environmental contamination in the cell suspension (Lorsch, Collins and Lippincott-Schwartz 2014).
The limitation can be said that there was no positive control. A positive control could be more supportive to interpret the data more accurately such as histograms and fluorescence level in flow cytometry (Althubiti and Macip 2017). Additionally, a good aseptic technique could result more live cells to be tested. Additional experiments with different monoclonal antibodies could generate more explainable and comparable data (Vongchan and Linhardt 2017). Total six different experiments were done, more cell lines could produce more comparable data for analysis.
Based on previous studies, it is inferred that TGF-β could induce EMT which has effect on cell-cell adhesion molecule E-cadherin. As TGF-β plays various types of roles in tissue culture technology, how to make good use of TGF-β as a double edge sword, will be the key research area in future.
Adan, A., Alizada, G., Kiraz, Y., Baran, Y. and Nalbant, A. (2017) ‘Flow Cytometry: Basic Principles and Applications’. Crit Rev Biotechnol, 37 (2), 163-176
Althubiti, M. and Macip, S. (2017) ‘Detection of Senescent Cells by Extracellular Markers Using a Flow Cytometry-Based Approach.’ in Oncogene-Induced Senescence: Methods and Protocols. ed. by Nikiforov, M. A. New York, NY: Springer New York, 147-153
Bertran, E., Crosas-Molist, E., Sancho, P., Caja, L., Lopez-Luque, J., Navarro, E., Egea, G., Lastra, R., Serrano, T., Ramos, E. and Fabregat, I. (2013) ‘Overactivation of the Tgf-Beta Pathway Confers a Mesenchymal-Like Phenotype and Cxcr4-Dependent Migratory Properties to Liver Tumor Cells’. Hepatology, 58 (6), 2032-2044
Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L. and Moses, H. L. (2001) ‘Transforming Growth Factor-Beta1 Mediates Epithelial to Mesenchymal Transdifferentiation through a Rhoa-Dependent Mechanism’. Mol Biol Cell, 12 (1), 27-36
Bierie, B. and Moses, H. L. (2006) ‘Tumour Microenvironment: Tgfbeta: The Molecular Jekyll and Hyde of Cancer’. Nat Rev Cancer, 6 (7), 506-520
Caja, L., Sancho, P., Bertran, E. and Fabregat, I. (2011) ‘Dissecting the Effect of Targeting the Epidermal Growth Factor Receptor on Tgf-Beta-Induced-Apoptosis in Human Hepatocellular Carcinoma Cells’. J Hepatol, 55 (2), 351-358
Cell Culture and Antibody Technology (1718OCTJAN) Mammalian Tissue Culture Labs Handout [online handout] module M12BMS, 17 November. Coventry: Coventry University. available from <https://cumoodle.coventry.ac.uk/mod/resource/view.php?id=1528867> [26 November 2017]
Chen, X., Rubock, M. J. and Whitman, M. (1996) ‘A Transcriptional Partner for Mad Proteins in Tgf-Beta Signalling’. Nature, 383 (6602), 691-696
Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L. C., Bapat, B., Gallinger, S., Andrulis, I. L., Thomsen, G. H., Wrana, J. L. and Attisano, L. (1996) ‘Madr2 Maps to 18q21 and Encodes a Tgfbeta-Regulated Mad-Related Protein That Is Functionally Mutated in Colorectal Carcinoma’. Cell, 86 (4), 543-552
Evans, R. J., Voelz, K., Johnston, S. A. and May, R. C. (2017) ‘Using Flow Cytometry to Analyze Cryptococcus Infection of Macrophages.’ in Phagocytosis and Phagosomes: Methods and Protocols. ed. by Botelho, R. New York, NY: Springer New York, 349-357
Fabregat, I., Fernando, J., Mainez, J. and Sancho, P. (2014) ‘Tgf-Beta Signaling in Cancer Treatment’. Curr Pharm Des, 20 (17), 2934-2947
Fernando, J., Malfettone, A., Cepeda, E. B., Vilarrasa-Blasi, R., Bertran, E., Raimondi, G., Fabra, A., Alvarez-Barrientos, A., Fernandez-Salguero, P., Fernandez-Rodriguez, C. M., Giannelli, G., Sancho, P. and Fabregat, I. (2015) ‘A Mesenchymal-Like Phenotype and Expression of Cd44 Predict Lack of Apoptotic Response to Sorafenib in Liver Tumor Cells’. Int J Cancer, 136 (4), E161-172
Fong, D., Duceppe, N. and Hoemann, C. D. (2017) ‘Mesenchymal Stem Cell Detachment with Trace Trypsin Is Superior to Edta for In vitro Chemotaxis and Adhesion Assays’. Biochemical and Biophysical Research Communications, 484 (3), 656-661
Fransvea, E., Angelotti, U., Antonaci, S. and Giannelli, G. (2008) ‘Blocking Transforming Growth Factor-Beta up-Regulates E-Cadherin and Reduces Migration and Invasion of Hepatocellular Carcinoma Cells’. Hepatology, 47 (5), 1557-1566
Giannelli, G., Fransvea, E., Marinosci, F., Bergamini, C., Colucci, S., Schiraldi, O. and Antonaci, S. (2002) ‘Transforming Growth Factor-Beta1 Triggers Hepatocellular Carcinoma Invasiveness Via Alpha3beta1 Integrin’. Am J Pathol, 161 (1), 183-193
Gotzmann, J., Huber, H., Thallinger, C., Wolschek, M., Jansen, B., Schulte-Hermann, R., Beug, H. and Mikulits, W. (2002) ‘Hepatocytes Convert to a Fibroblastoid Phenotype through the Cooperation of Tgf-Beta1 and Ha-Ras: Steps Towards Invasiveness’. J Cell Sci, 115 (Pt 6), 1189-1202
Jonas, S., Bechstein, W. O., Steinmuller, T., Herrmann, M., Radke, C., Berg, T., Settmacher, U. and Neuhaus, P. (2001) ‘Vascular Invasion and Histopathologic Grading Determine Outcome after Liver Transplantation for Hepatocellular Carcinoma in Cirrhosis’. Hepatology, 33 (5), 1080-1086
Kim, J., Johnson, K., Chen, H. J., Carroll, S. and Laughon, A. (1997) ‘Drosophila Mad Binds to DNA and Directly Mediates Activation of Vestigial by Decapentaplegic’. Nature, 388 (6639), 304-308
Kucsera, J., Yarita, K. and Takeo, K. (2000) ‘Simple Detection Method for Distinguishing Dead and Living Yeast Colonies’. J Microbiol Methods, 41 (1), 19-21
Lagna, G., Hata, A., Hemmati-Brivanlou, A. and Massague, J. (1996) ‘Partnership between Dpc4 and Smad Proteins in Tgf-Beta Signalling Pathways’. Nature, 383 (6603), 832-836
Levy, L. and Hill, C. S. (2006) ‘Alterations in Components of the Tgf-Beta Superfamily Signaling Pathways in Human Cancer’. Cytokine Growth Factor Rev, 17 (1-2), 41-58
Lorsch, J. R., Collins, F. S. and Lippincott-Schwartz, J. (2014) ‘Fixing Problems with Cell Lines: Technologies and Policies Can Improve Authentication’. Science (New York, N.y.), 346 (6216), 1452-1453
Macias-Silva, M., Abdollah, S., Hoodless, P. A., Pirone, R., Attisano, L. and Wrana, J. L. (1996) ‘Madr2 Is a Substrate of the Tgfbeta Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling’. Cell, 87 (7), 1215-1224
Massague, J. (2012) ‘Tgfbeta Signalling in Context’. Nat Rev Mol Cell Biol, 13 (10), 616-630
Massaous, J. and Hata, A. (1997) ‘Tgf-Beta Signalling through the Smad Pathway’. Trends Cell Biol, 7 (5), 187-192
Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S. and Giannelli, G. (2009) ‘Inhibition of Transforming Growth Factor Beta Receptor I Kinase Blocks Hepatocellular Carcinoma Growth through Neo-Angiogenesis Regulation’. Hepatology, 50 (4), 1140-1151
Miettinen, P. J., Ebner, R., Lopez, A. R. and Derynck, R. (1994) ‘Tgf-Beta Induced Transdifferentiation of Mammary Epithelial Cells to Mesenchymal Cells: Involvement of Type I Receptors’. J Cell Biol, 127 (6 Pt 2), 2021-2036
Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J., Heldin, C. H., Miyazono, K. and ten Dijke, P. (1997) ‘Tgf-Beta Receptor-Mediated Signalling through Smad2, Smad3 and Smad4’. Embo j, 16 (17), 5353-5362
Pagan, R., Sanchez, A., Martin, I., Llobera, M., Fabregat, I. and Vilaro, S. (1999) ‘Effects of Growth and Differentiation Factors on the Epithelial-Mesenchymal Transition in Cultured Neonatal Rat Hepatocytes’. J Hepatol, 31 (5), 895-904
Pelletier, J., Agonsanou, H., Delvalle, N., Fausther, M., Salem, M., Gulbransen, B. and Sévigny, J. (2017) ‘Generation and Characterization of Polyclonal and Monoclonal Antibodies to Human Ntpdase2 Including a Blocking Antibody’. Purinergic Signalling, 13 (3), 293-304
Radisky, D. C. (2005) ‘Epithelial-Mesenchymal Transition’. J Cell Sci, 118 (Pt 19), 4325-4326
Sanchez, P., Daniels, K. J., Park, Y. N. and Soll, D. R. (2014) ‘Generating a Battery of Monoclonal Antibodies against Native Green Fluorescent Protein for Immunostaining, Facs, Ip, and Chip Using a Unique Adjuvant’. Monoclon Antib Immunodiagn Immunother, 33 (2), 80-88
Serrano-Gomez, S. J., Maziveyi, M. and Alahari, S. K. (2016) ‘Regulation of Epithelial-Mesenchymal Transition through Epigenetic and Post-Translational Modifications’. Molecular Cancer, 15 (1), 18
Siegel, P. M. and Massague, J. (2003) ‘Cytostatic and Apoptotic Actions of Tgf-Beta in Homeostasis and Cancer’. Nat Rev Cancer, 3 (11), 807-821
Sumie, S., Kuromatsu, R., Okuda, K., Ando, E., Takata, A., Fukushima, N., Watanabe, Y., Kojiro, M. and Sata, M. (2008) ‘Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors’. Ann Surg Oncol, 15 (5), 1375-1382
Svendsen, A., Kiefer, H. V., Pedersen, H. B., Bochenkova, A. V. and Andersen, L. H. (2017) ‘Origin of the Intrinsic Fluorescence of the Green Fluorescent Protein’. J Am Chem Soc, 139 (25), 8766-8771
van Roy, F. and Berx, G. (2008) ‘The Cell-Cell Adhesion Molecule E-Cadherin’. Cell Mol Life Sci, 65 (23), 3756-3788
Vogelmann, R., Nguyen-Tat, M. D., Giehl, K., Adler, G., Wedlich, D. and Menke, A. (2005) ‘Tgfbeta-Induced Downregulation of E-Cadherin-Based Cell-Cell Adhesion Depends on Pi3-Kinase and Pten’. J Cell Sci, 118 (Pt 20), 4901-4912
Vongchan, P. and Linhardt, R. J. (2017) ‘Characterization of a New Monoclonal Anti-Glypican-3 Antibody Specific to the Hepatocellular Carcinoma Cell Line, Hepg2’. World Journal of Hepatology, 9 (7), 368-384
Xia, J. F., Gao, J. J., Inagaki, Y., Kokudo, N., Nakata, M. and Tang, W. (2013) ‘Flavonoids as Potential Anti-Hepatocellular Carcinoma Agents: Recent Approaches Using Hepg2 Cell Line’. Drug Discov Ther, 7 (1), 1-8
Yuan, F., Xiong, G., Cohen, N. A. and Cohen, A. S. (2017) ‘Optimized Protocol of Methanol Treatment for Immunofluorescent Staining in Fixed Brain Slices’. Applied Immunohistochemistry & Molecular Morphology, 25 (3), 221-224
Zhang, Y., Feng, X., We, R. and Derynck, R. (1996) ‘Receptor-Associated Mad Homologues Synergize as Effectors of the Tgf-Beta Response’. Nature, 383 (6596), 168-172
Zhang, Y., Musci, T. and Derynck, R. (1997) ‘The Tumor Suppressor Smad4/Dpc 4 as a Central Mediator of Smad Function’. Curr Biol, 7 (4), 270-276